Craft

Nykode Therapeutics

Stock Price

KR4.8

2024-10-29

Market Capitalization

KR1.6 B

2024-10-29

Revenue

$9.2 M

FY, 2024

Nykode Therapeutics Summary

Company Summary

Overview
Nykode Therapeutics (formerly known as Vaccibody) is a biopharmaceutical company dedicated to the discovery and development of immunotherapies. It utilizes a proprietary vaccine platform designed to generate antibody and T cell responses. Vaccibody product pipeline includes a therapeutic vaccine against cervical precancerous lesions and therapeutic cancer vaccines against tumor-specific antigens.
Type
Public
Status
Active
Founded
2007
HQ
Oslo, NO | view all locations
Website
https://nykode.com/
Cybersecurity rating
Sectors

Key People

  • Anders Tuv

    Anders Tuv, Chairman

    • Michael Engsig

      Michael Engsig, Chief Executive Officer

      • Mikkel W. Pedersen

        Mikkel W. Pedersen, Chief Scientific Officer

        • Harald Gurvin

          Harald Gurvin, Chief Financial Officer

          LocationsView all

          1 location detected

          • Oslo, Oslo HQ

            Norway

            Forskningsparken Aksjeselskap, Gaustadalléen 21

          Nykode Therapeutics Financials

          Summary Financials

          Revenue (Q1, 2025)
          $137.0K
          Gross profit (Q1, 2025)
          $137.0K
          Net income (Q1, 2025)
          ($1.4M)
          Cash (Q1, 2025)
          $106.2M
          EBIT (Q1, 2025)
          ($7.5M)
          Enterprise value
          $1.5B

          Footer menu